R & D
Osteoarthritis (OA) is one of the most common joint diseases and is characterized by the gradual degeneration of
cartilage over a long time (regressive degeneration). There is no cure, but treatments are available to manage symptoms.
It is said that the major cause of osteoarthritis is in degeneration of synovial fluid. Therefore, as one of the treatments, treatment is being administered in the joint of hyaluronic acid (HA), which is one component of synovial fluid.
Potential Disease-Modifying Effects of Jellyfish Mucin on OA
Lubricin is a mucinous glycoprotein and functions as both a boundary lubricant and chondroprotective agent in synovial joints. Recently, it has become clear that the lubricin prevents OA progression by enhancing the lubricating ability of synovial fluid.
Jellyfish mucin is similar to lubricin in structure.
Interactions between jellyfish mucin and hyaluronan in human chondrocytes, T. Takagaki, M. Sato, T. Kawake, T. Baba, K. Kihira, J. Mochida, International Journal of Biological and Pharmaceutial Research, 2015; 6(5): 351-358.
Jellyfish mucin may have potential disease modifying effects of osteoarthritis, N. Ohta, M. Sato,K. Ushida, M. Kokubo, T. Baba, K. Taniguchi, M. Urai, K. Kihira, J. Mochida, (98) BMC Biotechnology 9 (2009)